Regenxbio Inc. (RGNX) Trading Up 6.9%
Regenxbio Inc. (NASDAQ:RGNX)’s share price was up 6.9% during trading on Friday . The stock traded as high as $7.97 and last traded at $7.95, with a volume of 194,740 shares changing hands. The stock had previously closed at $7.44.
Several equities analysts recently commented on RGNX shares. Zacks Investment Research downgraded Regenxbio from a “hold” rating to a “sell” rating in a research note on Tuesday, March 22nd. Morgan Stanley boosted their target price on shares of Regenxbio from $34.00 to $36.00 in a report on Friday, April 8th. Chardan Capital reissued a “buy” rating on shares of Regenxbio in a report on Tuesday, May 10th. Finally, Piper Jaffray Cos. reissued a “buy” rating and set a $33.00 target price on shares of Regenxbio in a report on Tuesday, July 5th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $28.35.
The firm has a 50-day moving average of $10.01 and a 200-day moving average of $11.82. The stock’s market cap is $208.07 million.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.01. Equities analysts expect that Regenxbio Inc. will post ($2.37) EPS for the current year.
In related news, insider Fmr Llc sold 13,189 shares of the firm’s stock in a transaction that occurred on Wednesday, April 20th. The shares were sold at an average price of $11.66, for a total transaction of $153,783.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.